 Immunosuppressive Agents
"Immunosuppressive Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
| Descriptor ID |
D007166
|
| MeSH Number(s) |
D27.505.696.477.656
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunosuppressive Agents".
Below are MeSH descriptors whose meaning is more specific than "Immunosuppressive Agents".
This graph shows the total number of publications written about "Immunosuppressive Agents" by people in this website by year, and whether "Immunosuppressive Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 5 | 8 | | 1994 | 0 | 1 | 1 | | 1995 | 4 | 1 | 5 | | 1996 | 10 | 3 | 13 | | 1997 | 4 | 4 | 8 | | 1998 | 4 | 6 | 10 | | 1999 | 4 | 5 | 9 | | 2000 | 7 | 10 | 17 | | 2001 | 7 | 4 | 11 | | 2002 | 7 | 2 | 9 | | 2003 | 11 | 10 | 21 | | 2004 | 15 | 8 | 23 | | 2005 | 13 | 9 | 22 | | 2006 | 7 | 3 | 10 | | 2007 | 6 | 10 | 16 | | 2008 | 8 | 12 | 20 | | 2009 | 12 | 15 | 27 | | 2010 | 14 | 7 | 21 | | 2011 | 11 | 11 | 22 | | 2012 | 8 | 7 | 15 | | 2013 | 18 | 7 | 25 | | 2014 | 14 | 12 | 26 | | 2015 | 12 | 5 | 17 | | 2016 | 8 | 12 | 20 | | 2017 | 15 | 9 | 24 | | 2018 | 8 | 8 | 16 | | 2019 | 7 | 10 | 17 | | 2020 | 13 | 11 | 24 | | 2021 | 10 | 7 | 17 | | 2022 | 0 | 11 | 11 | | 2023 | 1 | 7 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunosuppressive Agents" by people in Profiles.
-
Bloom JL, Langford CA, Wechsler ME. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis. Rheum Dis Clin North Am. 2023 08; 49(3):563-584.
-
Vu TTT, Brown KK, Solomon JJ. Myositis-associated interstitial lung disease. Curr Opin Pulm Med. 2023 09 01; 29(5):427-435.
-
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. 2023 05 01; 46(5):1005-1013.
-
Malani Shukla N, Casper TC, Ness J, Wheeler Y, Chitnis T, Lotze T, Gorman M, Benson L, Weinstock-Guttmann B, Aaen G, Rodriguez M, Tillema JM, Krupp L, Schreiner T, Mar S, Goyal M, Rensel M, Abrams A, Rose J, Waltz M, Liu T, Manlius C, Waubant E. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Pediatr Neurol. 2023 Aug; 145:125-131.
-
Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, Peters M, Christoff GC, Sadatsafavi M, Torres-Duque CA, Altraja A, Lehtim?ki L, Papadopoulos NG, Salvi S, Costello RW, Cushen B, Heffler E, Iwanaga T, Al-Ahmad M, Larenas-Linnemann D, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Perez-de-Llano L, Perng Steve DW, Mahboub B, Wang E, Goh C, Lyu J, Newell A, Alacqua M, Belevskiy AS, Bhutani M, Bjermer L, Bjornsdottir U, Bourdin A, Bulow AV, Busby J, Canonica GW, Cosio BG, Dorscheid DR, Mu?oz-Esquerre M, FitzGerald JM, Gil EG, Gibson PG, Heaney LG, Hew M, Hilberg O, Hoyte F, Jackson DJ, Koh MS, Ko HB, Lee JH, Lehmann S, Chaves Loureiro C, L??v?ksd?ttir D, Menzies-Gow AN, Mitchell P, Papaioannou AI, Popov TA, Porsbjerg CM, Salameh L, Sirena C, Taill? C, Taube C, Tohda Y, Wechsler ME, Price DB. Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023 Jul; 78(7):1934-1948.
-
Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034.
-
Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Ferraro A, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani R, McAlear C, Moreland LW, Mynard K, Nachman P, Pagnoux C, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Wroe C, Jayne D, Merkel PA. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023 07; 82(7):937-944.
-
Almond CS, Sleeper LA, Rossano JW, Bock MJ, Pahl E, Auerbach S, Lal A, Hollander SA, Miyamoto SD, Castleberry C, Lee J, Barkoff LM, Gonzales S, Klein G, Daly KP. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. Am Heart J. 2023 06; 260:100-112.
-
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, B?dingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
-
Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, Boente RD, Donatelli JM, Dai J, Diaz FJ, Demoruelle MK, Hamblin MB, Mathai SK, Ryu JH, Pope K, Walker CM, Lee JS. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory. Chest. 2023 04; 163(4):861-869.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|